Atricure (ATRC) reported $535M in revenue for fiscal 2025, +14.9% year on year. That ranks #2171 by revenue among 2853 SEC filers and #209 in Healthcare. It posted a net loss of −$11.4M for the same year. Revenue has grown 16.3% a year on average since 2011 ($64.4M then). The fiscal 2025 balance sheet shows $654M in total assets, $167M in cash and $61.9M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $535M | +14.9% | FY20252025-12-31 |
| Gross profitGrossProfit | $401M | +15.3% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$9.4M | +$30.6M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$11.4M | +$33.3M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $57.3M | +369.8% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $9.1M | −21.0% | FY20252025-12-31 |
| Total assetsAssets | $654M | +7.4% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $492M | +6.7% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $167M | +36.4% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $61.9M | 0.0% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $141M | $108,000 | Open → |
| Q2 20262026-06-30 | $154M | $9.0M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Atricure, Inc.
- Ticker
- ATRC
- Exchange
- Nasdaq
- SIC classification
- Surgical & Medical Instruments & Apparatus (3841)
- Fiscal year end
- 12-31
- CIK
- 0001323885
Filings
- 10-QJul 27, 2026Open filing →
- 10-QMay 6, 2026Open filing →
- 10-KFeb 19, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| BioventusBVS | $568M | $22.7M |
| Organogenesis HoldingsORGO | $564M | $37.0M |
| HUTCHMED (China)HCM | $549M | $457M |
| AtricureATRC | $535M | −$11.4M |
| Mirum PharmaceuticalsMIRM | $521M | −$23.4M |
| VeracyteVCYT | $517M | $66.4M |
| InotivNOTVQ | $513M | −$68.6M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Atricure — Key figures |url=https://companiesranked.com/en/company/atricure |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Atricure — Key figures. CompaniesRanked. https://companiesranked.com/en/company/atricureBibTeX
@misc{companiesranked-en-company-atricure-2026,
author = {{CompaniesRanked}},
title = {{Atricure — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/atricure}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001323885-26-000007 · February 19, 2026
{{cite web |title=Atricure — Key figures — 10-K (0001323885-26-000007) |url=https://www.sec.gov/Archives/edgar/data/1323885/000132388526000007/atrc-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-19}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.